Reference entry
Tesa/IPA Protocol (Tesa-IPA)
Tesamorelin + Ipamorelin GH Secretagogue Blend
Overview
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common…
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a)…
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may effects.
Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
GH promotes protein synthesis and lean tissue preservation.
Mechanism
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common…
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a)…
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may effects.
Research areas
- The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common…
- The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a)…
- Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may effects.
- Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
- GH promotes protein synthesis and lean tissue preservation.
Research notes
- Injection site reactions (redness, itching)
- Water retention (usually transient)
- Tingling or numbness in extremities
- Increased hunger (Ipamorelin effect)
- Severe injection site reactions
References
Questions
Why combine tesamorelin and ipamorelin instead of using them separately?
Tesamorelin and ipamorelin work on complementary GH-release pathways (GHRH vs GHRP receptors), producing synergistic GH release greater than either alone. The combination mimics natural pulsatile GH secretion more effectively while maintaining safety with less cortisol/prolactin elevation than GHRPs used solo.
What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?
5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for athletic recovery; 10/3 for fat-loss focused protocols with body composition optimization goals.
Should the Tesa/IPA blend be taken on an empty stomach?
Yes, both tesamorelin and ipamorelin work best on an empty stomach (2-3 hours before eating). Evening injection (before bed) on an empty stomach optimizes the protocol by aligning with natural nighttime GH pulses and avoiding food-induced metabolic interference.
Can Tesa/IPA be combined with CJC-1295 or other GH secretagogues?
No, combining Tesa/IPA (which already contains both GHRH and GHRP pathways) with additional GHRPs or GHRH analogs risks excessive pituitary stimulation. The blend is specifically designed as a complete dual-pathway system that shouldn't require additional GH secretagogues.